FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

Eisai and MSD’s Liver Cancer Drug Secures NICE Nod

Jan. 3, 2019
A A

The National Institute for Health and Care excellence (NICE) has recommended NHS coverage for Eisai and MSD’s Lenvima (lenvatinib) for certain forms of liver cancer.

The drug will be made available for advanced liver cancer patients whose livers are well-functioning but who cannot be treated surgically. It works by cutting off the blood supply that leads to the growth and spread of cancer cells.

NICE based its recommendation on data that showed patients experienced a median overall survival of 13.6 months — more than a month longer than the alternative treatment Nexavar.

View today's stories